Recursion 从 Rallybio 获得 $12.5M，因为其罕见病药物 REV102 在试验中取得进展。 Recursion gets $12.5M from Rallybio as its rare disease drug REV102 advances in trials.

由于Rallybio的药物候选者REV102在治疗罕见基因紊乱的临床发展方面领先,Rallybio制药公司从Rallybio公司收到一笔1 250万美元的里程碑付款。 Recursion Pharmaceuticals received a $12.5 million milestone payment from Rallybio as its drug candidate REV102 advanced in clinical development for a rare genetic disorder. 这笔付款是由具体的监管和发展进展引发的,突出了两家公司之间正在进行的合作。 The payment was triggered by specific regulatory and developmental progress, highlighting the ongoing collaboration between the two companies. Recursion的专有平台正在支持药物的发展,资金将用于进一步临床试验和研究。 Recursion’s proprietary platform is supporting the drug’s development, with the funds intended to further clinical trials and research. 这一里程碑表明人们对REV102的潜力越来越有信心,并强调战略伙伴关系在推进稀有疾病的治疗方面的作用。 The milestone reflects growing confidence in REV102’s potential and underscores the role of strategic partnerships in advancing treatments for rare diseases.